Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/197222 
Erscheinungsjahr: 
2017
Quellenangabe: 
[Journal:] Health Economics Review [ISSN:] 2191-1991 [Volume:] 7 [Issue:] 26 [Publisher:] Springer [Place:] Heidelberg [Year:] 2017 [Pages:] 1-14
Verlag: 
Springer, Heidelberg
Zusammenfassung: 
The administration of (biologically-derived) drugs for various disease conditions involves consumption of resources that constitutes a direct monetary cost to healthcare payers and providers. An often ignored cost relates to a mismatch between patients' preferences and the mode of drug administration. The 'intangible' benefits of giving patients what they want in terms of the mode of drug delivery is seldom considered. This study aims to evaluate, in monetary terms, end-user preferences for the non-monetary attributes of different modes of drug administration using a discrete-choice experiment. It provides empirical support to the notion that there are significant benefits from developing patient-friendly approaches to drug delivery. The gross benefits per patient per unit administration is in the same order of magnitude as the savings in resource costs of administering drugs. The study argues that, as long as the underlying manufacturing science is capable, a patient-centred approach to producing drug delivery systems should be encouraged and pursued.
Schlagwörter: 
Discrete-choice experiments
Drug administration
Manufacturing
United Kingdom
Persistent Identifier der Erstveröffentlichung: 
Creative-Commons-Lizenz: 
cc-by Logo
Dokumentart: 
Article

Datei(en):
Datei
Größe
962.43 kB





Publikationen in EconStor sind urheberrechtlich geschützt.